Cinven Sells Minority Stakes in SYNLAB; Labcorp and Elliott Become Minority Investors

Cinven has sold an indirect minority stake in SYNLAB to strategic investor Labcorp while funds advised by Elliott have agreed to sell their direct stake to Ephios Bidco (Cinven-controlled) and reinvest proceeds to become an indirect minority shareholder alongside Cinven, Labcorp and Qatar Holding. The transactions leave Cinven as majority shareholder of SYNLAB and create opportunities for collaboration (including bringing Labcorp specialty tests to Europe); the Elliott transaction remains subject to regulatory approvals and is expected to close in early 2025.